Stocktoria

Unicycive Therapeutics, Inc. UNCY

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-06-17

Unicycive Therapeutics, Inc. statistics & valuation

Market cap$222.7M
P / B7.4×
Return on equity-87.9%
Return on capital-97.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
-1898.20% -3077.60% 202020212022202320242025
Return on equity (%)
-60.80% -494.30% -87.90% 202020212022202320242025
Shares outstanding
8.5M 15.0M 15.2M 34.8M 11.4M 22.1M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-1109.80% -53.40% -640.80% -215.20% -116.00% -54.00% 202020212022202320242025
Free cash flow margin (%)
-1646.00% -2710.40% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$0.86 -$1.20 -$1.28 -$5.65 -$1.67 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin——-3077.6%-1898.2%——
Net margin——-4525.0%-1898.8%——
FCF margin——-2710.4%-1646.0%——
Return on assets-54.0%-116.0%-215.2%-640.8%-53.4%-1109.8%
Return on equity-87.9%-494.3%801.9%3875.1%-60.8%84.8%
Current ratio2.591.280.760.818.750.07

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.